Search

Displaying results 1641 - 1650 of 4599 in total
  1. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

  2. Drug

    Eprosartan

    go.drugbank.com/drugs/DB00876
    ApprovedInvestigational

    By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.

  3. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play … WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs.

  4. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer.

  5. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH).

  6. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256408] By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity

  7. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].

  8. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

  9. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    However, being on the controlled drug and substance act does not necessitate that the drug is approved for sale on the market.

  10. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]